Sarcoidosis: Clinical presentation, immunopathogenesis, and therapeutics

JAMA

Volumn 305, Issue 4, 2011, Pages 391-399

  Iannuzzi, Michael C ^a   Fontana, Joseph R ^b  

^a State University of New York Upstate Medical University: College of Medicine   (United States)

^b NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ANTIINFLAMMATORY AGENT; ATORVASTATIN; CD4 ANTIGEN; CHEMOKINE; CORTICOSTEROID; CYCLOSPORIN; CYTOKINE; ETANERCEPT; FLUORODEOXYGLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INFLIXIMAB; METHOTREXATE; MONOCLONAL ANTIBODY; PENTOXIFYLLINE; PHOSPHODIESTERASE INHIBITOR; PREDNISONE; RITUXIMAB;

ADULT; ANEMIA; ANGINA PECTORIS; ARTICLE; BLINDNESS; BONE MARROW SUPPRESSION; CARDIOMYOPATHY; CASE REPORT; CHRONIC DISEASE; CLINICAL ASSESSMENT; COMPUTER ASSISTED TOMOGRAPHY; CONGESTIVE HEART FAILURE; COUGHING; CYTOPENIA; DEMYELINATING DISEASE; DIAGNOSTIC TEST; DIGESTIVE SYSTEM PERFORATION; DISEASE COURSE; DISEASE EXACERBATION; DRUG CYTOTOXICITY; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DYSPNEA; FATIGUE; FEMALE; FETUS DEATH; FETUS MALFORMATION; GASTROINTESTINAL TOXICITY; GENETICS; GRANULOMA; HEART ARRHYTHMIA; HELPER CELL; HEMOLYTIC UREMIC SYNDROME; HEPATITIS; HISTOPATHOLOGY; HUMAN; HYPERCALCEMIA; HYPERTENSION; IMMUNE DEFICIENCY; IMMUNOPATHOGENESIS; INFECTION; INTERSTITIAL PNEUMONIA; INTESTINE OBSTRUCTION; INTESTINE PERFORATION; INTROSPECTION; KIDNEY DISEASE; KIDNEY FAILURE; LABORATORY TEST; LIVER CIRRHOSIS; LIVER DYSFUNCTION; LIVER FUNCTION TEST; LIVER NECROSIS; LIVER TOXICITY; LUNG BIOPSY; LUNG FIBROSIS; LUPUS LIKE SYNDROME; LYMPH NODE BIOPSY; LYMPHOCYTE ACTIVATION; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MORBIDITY; MYALGIA; NEPHROTOXICITY; NEUROLOGIC DISEASE; PANCREATITIS; PATIENT CARE; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROGNOSIS; PULMONARY HYPERTENSION; RHABDOMYOLYSIS; SARCOIDOSIS; SIDE EFFECT; SIGNAL TRANSDUCTION; SKIN TOXICITY; SPLENOMEGALY; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT FAILURE; TREATMENT INDICATION; UVEITIS;

EID: 79251525181     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2011.10     Document Type: Article

References (50)

1. Boeck C. Multiple benign sarcoid of the skin. J Cutan Genitourin Did. 1899;17:543-550.
2. Rybicki BA, Major M, Popovich J Jr, Maliarik MJ, Iannuzzi MC. Racial differences in sarcoidosis incidence: a 5-year study in a health maintenance organization. Am J Epidemiol. 1997;145(3):234-241. (Pubitemid 27057175)
3. Baughman RP, Teirstein AS, Judson MA, et al; Case Control Etiologic Study of Sarcoidosis (ACCESS) research group. Clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir Crit Care Med. 2001;164(10 pt 1):1885-1889.
4. Newman LS, Rose CS, Bresnitz EA, et al; ACCESS Research Group. A Case Control Etiologic Study of Sarcoidosis: environmental and occupational risk factors. Am J Respir Crit Care Med. 2004;170(12):1324-1330.
5. Judson MA, Thompson BW, Rabin DL, et al; ACCESS Research Group. The diagnostic pathway to sarcoidosis. Chest. 2003;123(2):406-412.
6. Fisher KA, Serlin DM,Wilson KC, Walter RE, Berman JS, Farber HW. Sarcoidosis-associated pulmonary hypertension: outcome with long-term epoprostenol treatment. Chest. 2006;130(5):1481-1488. (Pubitemid 44786743)
7. Shorr AF, Helman DL, Davies DB, Nathan SD. Pulmonary hypertension in advanced sarcoidosis: epidemiology and clinical characteristics. Eur Respir J. 2005;25(5):783-788.
8. Bonfioli AA, Orefice F. Sarcoidosis. Semin Ophthalmol. 2005;20(3):177-182.
9. Mehta D, Lubitz SA, Frankel Z, et al. Cardiac involvement in patients with sarcoidosis: diagnostic and prognostic value of outpatient testing. Chest. 2008;133(6):1426-1435.
10. Kim JS, Judson MA, Donnino R, et al. Cardiac sarcoidosis. Am Heart J. 2009;157(1):9-21.
11. Ohira H, Tsujino I, Ishimaru S, et al. Myocardial imaging with 18F-fluoro-2-deoxyglucose positron emission tomography and magnetic resonance imaging in sarcoidosis. Eur J Nucl Med Mol Imaging. 2008;35(5):933-941.
12. Patel MR, Cawley PJ, Heitner JF, et al. Detection of myocardial damage in patients with sarcoidosis. Circulation. 2009;120(20):1969-1977.
13. Kellinghaus C, Schilling M, Lüdemann P. Neurosarcoidosis: clinical experience and diagnostic pitfalls. Eur Neurol. 2004;51(2):84-88.
14. Bihan H, Christozova V, Dumas JL, et al. Sarcoidosis: clinical, hormonal, and magnetic resonance imaging (MRI) manifestations of hypothalamicpituitary disease in 9 patients and review of the literature. Medicine (Baltimore). 2007;86(5):259-268. (Pubitemid 47415004)
15. Lower EE, Weiss KL. Neurosarcoidosis. Clin Chest Med. 2008;29(3):475-492, ix.
16. Yeager H, Rossman MD, Baughman RP, et al; ACCESS Research Group. Pulmonary and psychosocial findings at enrollment in the ACCESS study. Sarcoidosis Vasc Diffuse Lung Dis. 2005;22(2):147-153.
17. Garwood S, Judson MA, Silvestri G, Hoda R, Fraig M, Doelken P. Endobronchial ultrasound for the diagnosis of pulmonary sarcoidosis. Chest. 2007;132(4):1298-1304.
18. Teirstein AS, Machac J, Almeida O, Lu P, Padilla ML, Iannuzzi MC. Results of 188 whole-body fluorodeoxyglucose positron emission tomography scans in 137 patients with sarcoidosis. Chest. 2007;132(6):1949-1953.
19. Iannuzzi MC, Rybicki BA, Teirstein AS. Sarcoidosis. N Engl J Med. 2007;357(21):2153-2165.
20. Schutt AC, Bullington WM, Judson MA. Pharmacotherapy for pulmonary sarcoidosis: a Delphi consensus study. Respir Med. 2010;104(5):717-723.
21. Iannuzzi MC.Genetics of sarcoidosis. Monaldi Arch Chest Dis. 1998;53(6):609-613.
22. RybickiBA,IannuzziMC,FrederickMM,etal;ACCESS Research Group. Familial aggregation of sarcoidosis: ACase Control Etiologic Study of Sarcoidosis (ACCESS). Am J Respir Crit Care Med. 2001;164(11):2085-2091.
23. Hofmann S, Franke A, Fischer A, et al. Genomewide association study identifies ANXA11 as a new susceptibility locus for sarcoidosis [published correction appears in NatGenet. 2009;41(4):504]. Nat Genet. 2008;40(9):1103- 1106.
24. Iannuzzi MC, Iyengar SK, Gray-McGuire C, et al. Genome-wide search for sarcoidosis susceptibility genes in African Americans. Genes Immun. 2005;6(6):509-518.
25. Rybicki BA, Walewski JL, Maliarik MJ, Kian H, Iannuzzi MC; ACCESS Research Group. The BTNL2 gene and sarcoidosis susceptibility in African Americans and whites. Am J Hum Genet. 2005;77(3):491-499.
26. Valentonyte R, Hampe J, Huse K, et al. Sarcoidosis is associated with a truncating splice site mutation in BTNL2. Nat Genet. 2005;37(4):357-364.
27. Chen ES, Song Z, Willett MH, et al. Serum amyloid A regulates granulomatous inflammation in sarcoidosis through toll-like receptor-2. Am J Respir Crit Care Med. 2010;181(4):360-373.
28. Müller-Quernheim J, Schürmann M, Hofmann S, et al. Genetics of sarcoidosis. Clin Chest Med. 2008;29(3):391-414, viii.
29. Song Z, Marzilli L, Greenlee BM, et al. Mycobacterial catalase-peroxidase is a tissue antigen and target of the adaptive immune response in systemic sarcoidosis. J Exp Med. 2005;201(5):755-767.
30. Co DO, Hogan LH, Il-Kim S, Sandor M. T cell contributions to the different phases of granuloma formation. Immunol Lett. 2004;92(1-2):135-142. (Pubitemid 38470060)
31. Chen ES, Moller DR. Etiology of sarcoidosis. Clin Chest Med. 2008;29(3):365-377, vii.
32. Statement on sarcoidosis: Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am J Respir Crit Care Med. 1999;160(2):736-755.
33. Pinkston P, Bitterman PB, Crystal RG. Spontaneous release of interleukin-2 by lung T lymphocytes in active pulmonary sarcoidosis. N Engl J Med. 1983;308(14):793-800.
34. Robinson BW,McLemore TL, Crystal RG. Gamma interferon is spontaneously released by alveolar macrophages and lung T lymphocytes in patients with pulmonary sarcoidosis. J Clin Invest. 1985;75(5):1488-1495.
35. Shigehara K, Shijubo N, Ohmichi M, et al. IL-12 and IL-18 are increased and stimulate IFN-gamma production in sarcoid lungs. J Immunol. 2001;166 (1):642-649.
36. Agostini C, Meneghin A, Semenzato G. T-lymphocytes andcytokines in sarcoidosis. Curr Opin Pulm Med. 2002;8(5):435-440.
37. Chan ES, Cronstein BN. Molecular action of methotrexate in inflammatory diseases. Arthritis Res. 2002;4(4):266-273.
38. Baughman RP, Drent M, Kavuru M, et al; Sarcoidosis Investigators. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med. 2006;174(7):795-802.
39. Marques LJ, Zheng L, Poulakis N, Guzman J, Costabel U. Pentoxifylline inhibits TNF-alpha production from human alveolar macrophages. Am J Respir Crit Care Med. 1999;159(2):508-511.
40. Zabel P, Entzian P, Dalhoff K, Schlaak M. Pentoxifylline in treatment of sarcoidosis. Am J Respir Crit Care Med. 1997;155(5):1665-1669.
41. Park MK, Fontana JR Jr, Babaali H, et al. Steroidsparing effects of pentoxifylline in pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2009;26(2):121-131.
42. Kinlay S, Schwartz GG, Olsson AG, et al; Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering Study Investigators. High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study. Circulation. 2003;108(13):1560-1566.
43. Jain MK, Ridker PM. Anti-inflammatory effects of statins: clinical evidence and basic mechanisms. Nat Rev Drug Discov. 2005;4(12):977-987.
44. Kwak B, Mulhaupt F, Myit S, Mach F. Statins as a newly recognized type of immunomodulator. Nat Med. 2000;6(12):1399-1402.
45. Giembycz MA. Phosphodiesterase-4: selective and dual-specificity inhibitors for the therapy of chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2005;2(4):326-333.
46. Wyser CP, van Schalkwyk EM, Alheit B, Bardin PG, Joubert JR. Treatment of progressive pulmonary sarcoidosis with cyclosporin A: a randomized controlled trial. Am J Respir Crit Care Med. 1997;156(5):1371-1376.
47. Martinet Y, Pinkston P, Saltini C, Spurzem J, Müller-Quernheim J, Crystal RG. Evaluation of the in vitro and in vivo effects of cyclosporine on the lung T-lymphocyte alveolitis of active pulmonary sarcoidosis. Am Rev Respir Dis. 1988;138(5):1242-1248.
48. Utz JP, Limper AH, Kalra S, et al. Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis. Chest. 2003;124(1):177-185.
49. Baughman RP, Winget DB, Lower EE. Methotrexate is steroid sparing in acute sarcoidosis: results of a double blind, randomized trial. Sarcoidosis Vasc Diffuse Lung Dis. 2000;17(1):60-66.
50. Conti M, Beavo J. Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling. Annu Rev Biochem. 2007;76:481-511.